Skip to content

Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer

Feasibility Study of a Home-Based Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03672396
Enrollment
22
Registered
2018-09-14
Start date
2017-04-01
Completion date
2019-12-31
Last updated
2021-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgen Deprivation Therapy, Castration-resistant Prostate Cancer

Keywords

exercise, hormone therapy

Brief summary

This single arm, multi-site pilot study aims to evaluate the feasibility of recruiting and adherence to a 12 week home-based exercise intervention to be conducted in men with metastatic castration resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Thirty patients will be enrolled, with the expectation that 20-25 will complete all follow-up measures.

Detailed description

The purpose of this trial is to evaluate the feasibility and adherence to a home-based 12 week exercise intervention in mCRPC patients receiving ADT. It will also examine if a home-based exercise intervention can improve muscle strength, body composition, physical function, cardiopulmonary function fatigue, and patient reported outcomes (fatigue, depression, quality of life (QoL)).

Interventions

BEHAVIORALHome-based exercise

The intervention consists of aerobic and strength training \ 3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.

Sponsors

Wake Forest University Health Sciences
CollaboratorOTHER
UNC Lineberger Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Single-arm study with \ 30 men being recruited and 20-25 who complete all aspects of the study.

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Metastatic disease that has progressed despite castrate levels of testosterone (surgically or medically castrated, with testosterone levels of \< 50 ng/dL) receiving ADT. This will be verified by assessing total testosterone levels within 4 weeks prior to enrollment. * No current chemotherapy. * Patients may be receiving additional hormonal therapy agents including but not limited to antiandrogens (e.g. bicalutamide, enzalutamide) and CYP17 inhibitors (e.g. abiraterone). * Ability to engage safely in moderate exercise as determined by their treating physician. * Not previously engaged in regular exercise training (\<3 or more d/wk for \> 30 min/d or \<90 mins per week total including strength training, aerobic training, or walking) in the past 6 months. * Access to a computer or a smart phone for syncing and uploading wearable activity data. * Be able to speak and read English.

Exclusion criteria

* Any condition that causes severe pain with exertion. * History of bone fractures. * Active cardiovascular disease including any of the following: * New York Heart Association (NYHA) Grade II or greater congestive heart failure . * History of myocardial infarction or unstable angina within 6 months prior to Day 1. * History of stroke or transient ischemic attack within 6 months prior to Day 1. * Acute or chronic respiratory disease that is severe enough to compromise the ability of the participant to safely engage in exercise training protocol. * Acute or chronic bone/joint/muscular abnormalities compromising their ability to exercise. * Neurological conditions that affect balance and, or muscle strength. * Dementia, altered mental status or any psychiatric condition prohibiting the understanding or rendering of informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing.12 weeks after baseline testingTo estimate the feasibility of a 12 week, home-based exercise intervention in metastatic castrate resistant prostate cancer (mCPRC) patients undergoing androgen deprivation therapy by reporting the percentage of patients who complete the pre/post testing following the intervention. This was calculated as the number of subjects who completed the trial compared to the total number who completed baseline testing.

Secondary

MeasureTime frameDescription
Physical Function: 6m Walk12 weeks after baseline testingThe time to complete (in sec) the 6m rapid walk test will be performed.
Physical Function: Timed Up and Go12 weeks after baseline testingThe time to complete (in sec) the 2.44m (8 ft) timed up and go test will be performed as an indicator of agility, balance, and physical function. A lower total time is indicative of greater performance.
Physical Function: Stair Climb12 weeks after baseline testingThe time to climb a flight of stairs (in sec) will be performed as an indicator of functional strength, muscle power, and balance. A lower total time (and higher calculated power output) is indicative of greater performance.
Physical Function: 400m Walk12 weeks after baseline testingThe time to walk 400m (in sec) will be performed as an indicator of walking endurance and gait speed will be determined. A lower total time and higher gait speed indicates greater cardiorespiratory capacity and will be correlated with cardiopulmonary function scores (outcome 14).
Patient Reported Outcomes: Fatigue12 weeks after baseline testingFatigue will be measure using the Functional Assessment of Chronic Illness Therapy Fatigue, a 1 page form that uses a rating scale that goes from 0 to 52. It assesses the patient's fatigue levels in the last 7 days. It also measures how usual activities, performing work, walking, relationship, and enjoyment of life are affected by fatigue. A higher score indicates higher quality of life (and lower fatigue).
Patient Reported Outcomes: Quality of Life12 weeks after baseline testingQuality of life will be measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The FACT-P is composed of both multi-item scales and single-item measures. These include physical, social, emotional, and functional well-being, along with an assessment of prostate-specific health status. five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the individual questions are scored from 0-4 with total scores ranging between 0 and 156 where a higher number represents higher QoL.
Patient Reported Outcomes: Depression12 weeks after baseline testingDepression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression.
Patient Reported Outcomes: Anxiety12 weeks after baseline testingDepression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression.
Muscle Size (Cross-sectional Area)12 weeks after baseline testingMuscle size will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle size. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality.
Adherence to the Intervention12 weeks after baseline testingTo report the level of adherence to the exercise intervention in patients completing pre/post testing. Successful adherence to the program is completion of 75% of all prescribed exercise and will be assessed using wearable technology to track walking and exercise logs to track resistance training adherence. Adherence was determined as the number of exercise sessions attempted/completed over the total number of session prescribed.
Chest Press Maximal Strength12 weeks after baseline testingUpper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL.
Chest Press Muscle Endurance12 weeks after baseline testingUpper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL.
Leg Press Maximal Strength12 weeks after baseline testingUpper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL.
Leg Press Muscle Endurance12 weeks after baseline testingUpper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL.
Cardiopulmonary Function12 weeks after baseline testingTo report changes in cardiopulmonary function following the intervention. Cardiopulmonary function (VO2 peak) will be assessed using a graded exercise test on a treadmill. Patients will begin the test walking slowly on the treadmill and every two minutes, the grade and speed of the treadmill will be increased in a progressive manner until fatigue occurs. Respiratory gases will be collected throughout the test and analyzed using a metabolic cart to determine oxygen utilization and carbon dioxide production. The maximal oxygen uptake that is recorded will be used as a marker of aerobic fitness.
Lean Mass12 weeks after baseline testingTo report changes in total lean mass following the intervention. Total body lean mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention.
Fat Mass12 weeks after baseline testingTo report changes in total fat mass following the intervention. Total fat mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention.
Percent Body Fat12 weeks after baseline testingTo report changes in relative fat mass following the intervention. Total body percent fat (percentage of fat mass relative to total mass) will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention.
Muscle Quality12 weeks after baseline testingMuscle architecture will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle quality. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality. Muscle quality is reported in arbitrary units, where a lower value indicates a higher/better muscle quality.

Countries

United States

Participant flow

Recruitment details

Subjects were recruited from 4/16/2017 through 12/5/2019 from referrals from medical oncologists from three institutions.

Pre-assignment details

62 subjects were referred to the study. Of this, 40 did not participate or qualify for the study. 22 subjects were consented and 16 completed all aspects of the trial.

Participants by arm

ArmCount
Home-based Exercise
The sole intervention group will complete a combination of aerobic and strength training \ 3 times per week for 12 weeks with each session lasting 1 hour. Home-based exercise: The intervention consists of aerobic and strength training \ 3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.
16
Total16

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event1
Overall StudyPhysician Decision1
Overall StudyWithdrawal by Subject4

Baseline characteristics

CharacteristicHome-based Exercise
Age, Continuous72 years
STANDARD_DEVIATION 7
Body Mass Index28.90 kg/m^2
STANDARD_DEVIATION 6
Duration of Androgen Deprivation Therapy (ADT)1132 days
STANDARD_DEVIATION 1369
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
16 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Height172.4 cm
STANDARD_DEVIATION 4.6
Mass86.2 kg
STANDARD_DEVIATION 19.6
Previous Chemotherapy5 Participants
Previous Prostatectomy7 Participants
Previous Radiotherapy11 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
3 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
13 Participants
Region of Enrollment
United States
16 participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
16 Participants
Time since Chemotherapy13 months
STANDARD_DEVIATION 5

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 22
other
Total, other adverse events
1 / 22
serious
Total, serious adverse events
0 / 22

Outcome results

Primary

Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing.

To estimate the feasibility of a 12 week, home-based exercise intervention in metastatic castrate resistant prostate cancer (mCPRC) patients undergoing androgen deprivation therapy by reporting the percentage of patients who complete the pre/post testing following the intervention. This was calculated as the number of subjects who completed the trial compared to the total number who completed baseline testing.

Time frame: 12 weeks after baseline testing

Population: All participants in the trial.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Home-based ExercisePercentage of Patients Who Complete the Pre/Post Exercise Intervention Testing.16 Participants
Secondary

Adherence to the Intervention

To report the level of adherence to the exercise intervention in patients completing pre/post testing. Successful adherence to the program is completion of 75% of all prescribed exercise and will be assessed using wearable technology to track walking and exercise logs to track resistance training adherence. Adherence was determined as the number of exercise sessions attempted/completed over the total number of session prescribed.

Time frame: 12 weeks after baseline testing

Population: This analysis was restricted to subjects who completed the intervention and returned their training logs.

ArmMeasureGroupValue (NUMBER)
Home-based ExerciseAdherence to the InterventionOverall80.1 percentage of total sessions prescribed
Home-based ExerciseAdherence to the InterventionWalking65.5 percentage of total sessions prescribed
Home-based ExerciseAdherence to the InterventionResistance Training72.8 percentage of total sessions prescribed
Secondary

Cardiopulmonary Function

To report changes in cardiopulmonary function following the intervention. Cardiopulmonary function (VO2 peak) will be assessed using a graded exercise test on a treadmill. Patients will begin the test walking slowly on the treadmill and every two minutes, the grade and speed of the treadmill will be increased in a progressive manner until fatigue occurs. Respiratory gases will be collected throughout the test and analyzed using a metabolic cart to determine oxygen utilization and carbon dioxide production. The maximal oxygen uptake that is recorded will be used as a marker of aerobic fitness.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExerciseCardiopulmonary FunctionBaseline19.3 mL/kg/minStandard Deviation 4
Home-based ExerciseCardiopulmonary FunctionPost Intervention20.1 mL/kg/minStandard Deviation 5.6
p-value: 0.05795% CI: [-0.04, 2.6]t-test, 2 sided
Secondary

Chest Press Maximal Strength

Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExerciseChest Press Maximal StrengthBaseline62.4 kgStandard Deviation 21.4
Home-based ExerciseChest Press Maximal StrengthPost Intervention62.0 kgStandard Deviation 13.3
p-value: 0.94595% CI: [-13.5, 12.7]t-test, 2 sided
Secondary

Chest Press Muscle Endurance

Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExerciseChest Press Muscle EnduranceBaseline14.1 number of repetitions completedStandard Deviation 5
Home-based ExerciseChest Press Muscle EndurancePost Intervention15.4 number of repetitions completedStandard Deviation 6.8
p-value: 0.4295% CI: [-2, 4.6]t-test, 2 sided
Secondary

Fat Mass

To report changes in total fat mass following the intervention. Total fat mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and completed the body composition scans.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExerciseFat MassBaseline30 kgStandard Deviation 12.9
Home-based ExerciseFat MassPost Intervention28.4 kgStandard Deviation 15.2
p-value: 0.19195% CI: [-0.3, 1.1]t-test, 2 sided
Secondary

Lean Mass

To report changes in total lean mass following the intervention. Total body lean mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and the body composition scans.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExerciseLean MassBaseline54.5 kgStandard Deviation 8.6
Home-based ExerciseLean MassPost Intervention51.4 kgStandard Deviation 16
p-value: 0.80995% CI: [-1, 1.3]t-test, 2 sided
Secondary

Leg Press Maximal Strength

Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExerciseLeg Press Maximal StrengthBaseline142.1 kgStandard Deviation 49.1
Home-based ExerciseLeg Press Maximal StrengthPost Intervention141.5 kgStandard Deviation 52
p-value: 0.94195% CI: [-16.9, 15.8]t-test, 2 sided
Secondary

Leg Press Muscle Endurance

Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExerciseLeg Press Muscle EndurancePost Intervention14.1 number of repetitions completedStandard Deviation 6.4
Home-based ExerciseLeg Press Muscle EnduranceBaseline11.8 number of repetitions completedStandard Deviation 6.7
p-value: 0.20395% CI: [-1.4, 5.9]t-test, 2 sided
Secondary

Muscle Quality

Muscle architecture will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle quality. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality. Muscle quality is reported in arbitrary units, where a lower value indicates a higher/better muscle quality.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExerciseMuscle QualityBaseline110.2 unitlessStandard Deviation 22
Home-based ExerciseMuscle QualityPost Intervention114.3 unitlessStandard Deviation 16.6
p-value: 0.36995% CI: [-5.54, 13.85]t-test, 2 sided
Secondary

Muscle Size (Cross-sectional Area)

Muscle size will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle size. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the University of North Carolina (UNC) site only. Equipment to perform this analysis at the Wake Forest site was not available.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExerciseMuscle Size (Cross-sectional Area)Baseline8.3 cm^2Standard Deviation 2.9
Home-based ExerciseMuscle Size (Cross-sectional Area)Post Intervention10.2 cm^2Standard Deviation 4
p-value: 0.01395% CI: [0.48, 3.29]t-test, 2 sided
Secondary

Patient Reported Outcomes: Anxiety

Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExercisePatient Reported Outcomes: AnxietyBaseline4 score on a scaleStandard Deviation 3
Home-based ExercisePatient Reported Outcomes: AnxietyPost Intervention3 score on a scaleStandard Deviation 2
p-value: 0.27495% CI: [-2.3, 0.7]t-test, 2 sided
Secondary

Patient Reported Outcomes: Depression

Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExercisePatient Reported Outcomes: DepressionBaseline3 score on a scaleStandard Deviation 2
Home-based ExercisePatient Reported Outcomes: DepressionPost Intervention3 score on a scaleStandard Deviation 3
p-value: 0.59495% CI: [-1.1, 0.7]t-test, 2 sided
Secondary

Patient Reported Outcomes: Fatigue

Fatigue will be measure using the Functional Assessment of Chronic Illness Therapy Fatigue, a 1 page form that uses a rating scale that goes from 0 to 52. It assesses the patient's fatigue levels in the last 7 days. It also measures how usual activities, performing work, walking, relationship, and enjoyment of life are affected by fatigue. A higher score indicates higher quality of life (and lower fatigue).

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExercisePatient Reported Outcomes: FatigueBaseline39 score on a scaleStandard Deviation 10
Home-based ExercisePatient Reported Outcomes: FatiguePost Intervention40 score on a scaleStandard Deviation 11
p-value: 0.57995% CI: [-4.3, 7.2]t-test, 2 sided
Secondary

Patient Reported Outcomes: Quality of Life

Quality of life will be measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The FACT-P is composed of both multi-item scales and single-item measures. These include physical, social, emotional, and functional well-being, along with an assessment of prostate-specific health status. five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the individual questions are scored from 0-4 with total scores ranging between 0 and 156 where a higher number represents higher QoL.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExercisePatient Reported Outcomes: Quality of LifeBaseline119 score on a scaleStandard Deviation 20
Home-based ExercisePatient Reported Outcomes: Quality of LifePost Intervention119 score on a scaleStandard Deviation 16
p-value: 0.94895% CI: [-3.9, 3.7]t-test, 2 sided
Secondary

Percent Body Fat

To report changes in relative fat mass following the intervention. Total body percent fat (percentage of fat mass relative to total mass) will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and the body composition scans.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExercisePercent Body FatBaseline34.0 percentage of total body massStandard Deviation 6.1
Home-based ExercisePercent Body FatPost Intervention34.3 percentage of total body massStandard Deviation 6.6
p-value: 0.23795% CI: [-0.3, 1.3]t-test, 2 sided
Secondary

Physical Function: 400m Walk

The time to walk 400m (in sec) will be performed as an indicator of walking endurance and gait speed will be determined. A lower total time and higher gait speed indicates greater cardiorespiratory capacity and will be correlated with cardiopulmonary function scores (outcome 14).

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExercisePhysical Function: 400m WalkPost Intervention313.5 secondsStandard Deviation 87.3
Home-based ExercisePhysical Function: 400m WalkBaseline329.8 secondsStandard Deviation 97.8
p-value: 0.11195% CI: [-36.9, 4.3]t-test, 2 sided
Secondary

Physical Function: 6m Walk

The time to complete (in sec) the 6m rapid walk test will be performed.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExercisePhysical Function: 6m WalkBaseline4.4 secondsStandard Deviation 1.5
Home-based ExercisePhysical Function: 6m WalkPost Intervention4.5 secondsStandard Deviation 1.5
p-value: 0.37895% CI: [-0.2, 0.4]t-test, 2 sided
Secondary

Physical Function: Stair Climb

The time to climb a flight of stairs (in sec) will be performed as an indicator of functional strength, muscle power, and balance. A lower total time (and higher calculated power output) is indicative of greater performance.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExercisePhysical Function: Stair ClimbBaseline6.4 secondsStandard Deviation 2.8
Home-based ExercisePhysical Function: Stair ClimbPost Intervention6.2 secondsStandard Deviation 3.2
p-value: 0.25295% CI: [-0.7, 0.2]t-test, 2 sided
Secondary

Physical Function: Timed Up and Go

The time to complete (in sec) the 2.44m (8 ft) timed up and go test will be performed as an indicator of agility, balance, and physical function. A lower total time is indicative of greater performance.

Time frame: 12 weeks after baseline testing

Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial.

ArmMeasureGroupValue (MEAN)Dispersion
Home-based ExercisePhysical Function: Timed Up and GoBaseline10.4 secondsStandard Deviation 9.1
Home-based ExercisePhysical Function: Timed Up and GoPost Intervention10.8 secondsStandard Deviation 11
p-value: 0.58695% CI: [-1, 1.7]t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026